Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20317
Title: A randomised controlled trial of nasal decongestant to treat obstructive sleep apnoea in people with cervical spinal cord injury.
Austin Authors: Wijesuriya, Nirupama S;Eckert, Danny J;Jordan, Amy S ;Schembri, Rachel M ;Lewis, Chaminda;Meaklim, Hailey J ;Booker, Lauren;Brown, Doug ;Graco, Marnie ;Berlowitz, David J 
Affiliation: University of New South Wales, Sydney, NSW, Australia
Institute for Breathing and Sleep and Austin Health, Heidelberg, Victoria, Australia
The University of Melbourne, Melbourne, Victoria, Australia
Spinal Research Institute, Heidelberg, Victoria, Australia
Neuroscience Research Australia (NeuRA), Randwick, NSW, Australia
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Jul-2019
metadata.dc.date: 2019-02-13
Publication information: Spinal cord 2019; 57(7): 579-585
Abstract: Prospective, double-blind, randomised, placebo-controlled, cross-over trial of nasal decongestion in tetraplegia. Tetraplegia is complicated by severe, predominantly obstructive, sleep apnoea. First-line therapy for obstructive sleep apnoea is nasal continuous positive airway pressure, but this is poorly tolerated. High nasal resistance associated with unopposed parasympathetic activation of the upper airway contributes to poor adherence. This preliminary study tested whether reducing nasal decongestion improved sleep. Participants' homes in Melbourne and Sydney, Australia. Two sleep studies were performed in participants' homes separated by 1 week. Participants were given a nasal spray (0.5 mL of 5% phenylephrine or placebo) in random order and posterior nasal resistance measured immediately. Outcomes included sleep apnoea severity, perceived nasal congestion, sleep quality and oxygenation during sleep. Twelve middle-aged (average (SD) 52 (12) years) overweight (body mass index 25.3 (6.7) kg/m2) men (C4-6, AIS A and B) participated. Nasal resistance was reduced following administration of phenylephrine (p = 0.02; mean between treatment group difference -5.20: 95% confidence interval -9.09, -1.32 cmH2O/L/s). No differences were observed in the apnoea hypopnoea index (p = 0.15; -6.37: -33.3, 20.6 events/h), total sleep time (p = 0.49; -1.33: -51.8, 49.1 min), REM sleep% (p = 0.50; 2.37: -5.6, 10.3), arousal index (p = 0.76; 1.15: -17.45, 19.75), 4% oxygen desaturation index (p = 0.88; 0.63: -23.5, 24.7 events/h), or the percentage of mouth breathing events (p = 0.4; -8.07: -29.2, 13.0) between treatments. The apnoea hypopnoea index did differ between groups, however, all except one participant had proportionally more hypopnoeas than apnoeas during sleep after decongestion. These preliminary data found that phenylephrine acutely reduced nasal resistance but did not significantly change sleep-disordered breathing severity.
URI: http://ahro.austin.org.au/austinjspui/handle/1/20317
DOI: 10.1038/s41393-019-0256-6
ORCID: 0000-0001-6048-0147
0000-0003-2543-8722
PubMed URL: 30760846
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on May 6, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.